Primary bone lymphoma (PBL) is a rare disorder. We herein present a case of other iatrogenic immunodeficiency-associated lymphoproliferative disorder (OIIA-LPD) presenting as PBL. A 63-year-old woman was diagnosed with rheumatoid arthritis and had been treated with methotrexate for seven years. Two months before admission, she suffered from pain in the limbs. Magnetic resonance imaging revealed multiple irregular lesions in the bones of the limbs, which showed an uptake of 
Introduction
Primary bone lymphoma (PBL) is a rare disorder. It accounts for 5% of extranodal lymphomas (1) (2) (3) (4) (5) (6) , less than 1% of all non-Hodgkin's lymphomas (3, 6, 7) , and 3% of all primary malignant bone tumors (2, 5, 8) . Patients with rheumatoid arthritis (RA) tend to develop lymphoproliferative disorders (LPD) at a frequency of 2.0-5.5 times higher than that in the general population. However, its exact frequency in lymphomas is unknown (9, 10) . When LPD is diagnosed in patients treated with immunosuppressive therapy, it is categorized as other iatrogenic immunodeficiency-associated lymphoproliferative disorder (OIIA-LPD) according to the World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues. We herein present a case of RA with OIIA-LPD presenting as PBL. This case is helpful in the management of OIIA-LPD presenting as PBL due to its rarity and difficulty to diagnose and evaluate the response to therapy.
Case Report
A 63-year-old woman was referred to our hospital for the treatment of lymphoma. The patient was previously diagnosed with RA, which had been treated with methotrexate (MTX) for seven years. She had been asymptomatic until two months before this admission when pain in her limbs developed. Her rheumatologist suspected the exacerbation of RA; however, no physical or laboratory findings supported this suspicion. Magnetic resonance imaging (MRI) revealed multiple irregular lesions in the femurs, tibias, patellae, humeri, and radiuses (Fig. 1) . These lesions were hypointense on the T1-weighted image and hyperintense on T2-weighted, fat suppression, and diffusion-weighted images. Positron emission tomography/computed tomography (PET/CT) re- 
vealed an uptake of 18 F-FDG in these lesions (Fig. 2 ). Because these images indicated a malignant bone disorder, a biopsy of the right radius was performed. The biopsy findings showed pathological features of diffuse large B-cell lymphoma (DLBCL) (Fig. 3) . Epstein-Barr virus-encoded small RNA-1 (EBER-1) was negative. According to the WHO classification of tumors of the hematopoietic and lymphoid tissues, the diagnosis of OIIA-LPD was made (11) . Because the patient did not exhibit either lymphadenopathy or visceral lesions, such as hepatomegaly and splenomegaly, she fulfilled the criteria of PBL according to the WHO classification of tumors of soft tissue and bone (12) . She was admitted to the hospital after cessation of MTX for one month without regression.
A physical examination showed no superficial lymphadenopathy or hepatosplenomegaly. All laboratory data including a blood cell count, lactic acid dehydrogenase (LDH) and soluble interleukin-2 receptor (sIL-2R) were within normal ranges except for alkaline phosphatase (ALP) ( Table) . An iliac bone marrow biopsy showed no evidence of lymphoma infiltration. According to these findings, the clinical stage was evaluated as IVAEO+ (Ann Arbor classification) and international prognostic index (IPI) was 3 points (highintermediate risk).
We treated the patient with R-CHOP therapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone). After four cycles of this treatment, the hypointense lesions on the T1-weighted MRI image were decreased in size, but did not disappear (Fig. 4) . We then added two cycles of R-EPOCH therapy (rituximab, etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin) because the viability of the lesions was not evaluated correctly by MRI. After six cycles of chemotherapies, she achieved a complete response (CR) on PET/CT (Fig. 5) , which has been maintained for more than half a year. (2, 18). The present case is compatible with this unique entity. The etiology of PBL is unknown (6) . Some factors including HIV infection, sarcoidosis, renal transplantation, and cladribine therapy have been reported in association with PBL (18) . A retrospective study of LPD in patients with RA showed that the frequency of PBL was 2.6% (9) . It is of note that this is the first case to report precisely it's the clinical course of PBL occurring in an RA patient treated with MTX.
The most common symptom of PBL is bone pain (2, 3, 6-8, 13, 16). In patients with RA, it is important and occasionally difficult to distinguish pain of PBL from that of the exacerbation of RA. A physical examination, blood tests, and imaging studies, such as MRI and PET/CT, to exclude synovium inflammation of RA and to detect the bone lesion of PBL were useful in the present case. X-rays typically show focal lytic lesions or permeative destruction often with sclerotic change (6, 8, 15) . Unfortunately, a lesion of PBL may not be detected on X-rays such as in this case (8) . CT is useful to evaluate soft tissue extension of PBL (6, 15) . MRI is the most sensitive imaging study in the diagnosis of PBL. The lesion typically shows iso-to hypointense on the T1-weighted image and hyperintense on the T2-weighted image (6, 8, 15) . PET/CT is useful to assess the remission status of PBL (6, 8, 15, 19) . However, because all imaging study findings mentioned above are nonspecific, a bone biopsy is essential to make the diagnosis of PBL.
Due to its rarity, no standard therapy for PBL has yet been established. In the case of PBL with a single bone lesion with or without regional lymph nodes (IELSG stage IE or IIE), chemotherapy plus radiotherapy might be preferred. However, chemotherapy alone is indicated for PBL patients with multifocal bone disease (IELSG stage IVE or IV), as for this case (1-3, 6, 13) . The withdrawal of MTX reportedly caused spontaneous regression in approximately half of other iatrogenic immunodeficiency-associated lymphoproliferative disorder (OIID-LPD) cases. Spontaneous regression tended to occur in Epstein-Barr virus (EBV)-positive patients, which comprise 27.1-62.8% of OIID-LPD in Japan (9, 10) . However, the present case was negative for EBV and the one-month withdrawal of MTX did not lead to regression. We therefore selected the R-CHOP regimen as first-line therapy.
The five-year overall survival (OS) and progression-free survival (PFS) rates of PBL were reported to be 36.7-91% and 13.4-75.7%, respectively (1-4, 5-7, 13, 16) . Conversely, the five-year OS and PFS rates of multifocal bone DLBCL, such as this case, were reported to be 36.7-74% and 13.4-34%, respectively (1, 2) . Several studies have identified predictors of the prognosis of PBL. For instance, multifocality (1, 4, 5), age ! 60 years (1, 5, 8) , non-CR response (13) , soft tissue extension (3, 6) , increased IPI (3, 5), elevated LDH (5), and B symptom positive (5) were reported to be factors for a shorter survival. The present case appeared to have a poor prognosis due to multifocality, age ! 60 years and high-intermediate risk of IPI. We therefore decided to add two courses of R-EPOCH therapy after four cycles of R-CHOP therapy due to suspected insufficient responses on MRI and an estimated poor prognosis. This case achieved a CR on PET/CT after six cycles of chemotherapies and the CR has been maintained for more than half a year.
This case elucidates the importance of considering PBL in patients with RA complaining of bone pain. MRI and FDG-PET/CT confer clues for the diagnosis and biopsy site. A histologic examination of the biopsy specimen is mandatory for the diagnosis of lymphoma. This report is the first documentation of the clinical course of an OIIA-LPD case presenting as multifocal PBL.
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